NCT05987696View on ClinicalTrials.gov

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
AML, AdultMinimal Residual Disease
Interventions
DRUG

CD33/CLL1 dual CAR-NK cell

NK cell therapy

DRUG

Cyclophosphamid

Lympho-conditioning Agent

DRUG

Fludarabine

Lympho-conditioning Agent

DRUG

Cytarabine

Lympho-conditioning Agent

DRUG

CD33 CAR-NK cell

NK cell therapy

DRUG

super NK cell

NK cell therapy

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Hangzhou Qihan Biotech Co.,Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT05987696 - Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter